ArticleBMC urology2026
MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe objective of this study was to comprehensively characterize the expression profiles and prognostic significance of palmitoylation-related genes (PRGs) in bladder cancer (BLCA).
methodsTranscriptomic, clinical, and somatic mutation data of BLCA patients were obtained from The Cancer Genome Atlas (TCGA) and the GEO dataset (GSE13507), and batch effects were corrected using the ComBat method. Consensus clustering was performed to identify PRG-related molecular subtypes. Prognostic differentially expressed genes (DEGs) were further used for gene subtyping, and a PRG-based prognostic risk model was constructed by applying the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression. CIBERSORT assessed immune infiltration, while scRNA-seq data from Tumor Immune Single-cell Hub (TISCH) analyzed core gene expression in cell clusters. The biological function of the core gene was validated by Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR), Western blotting, wound-healing, colony-formation, and EdU assays.
resultsTwo distinct PRG-related molecular subtypes and two gene subtypes were identified. The nine core genes (including MXRA8) showed robust predictive performance (AUC > 0.7 for 1-, 3-, and 5-year overall survival) and was incorporated into a nomogram along with clinical parameters. MXRA8 was highly expressed in BLCA tissues at both transcript and protein levels and predominantly expressed in fibroblast and myofibroblast clusters. Functionally, silencing MXRA8 significantly suppressed BLCA cell proliferation, migration, and invasion.
conclusionsThe PRG-based risk score serves as a robust and clinically applicable tool for prognostic evaluation and predicting chemotherapy response. Furthermore, MXRA8 may serve as a potential molecular hub for developing precision medicine–oriented therapeutic strategies in BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.